Full-Time

Senior Manager Manufacturing

Production Process Owners

Updated on 8/1/2026

Amgen

Amgen

10,001+ employees

Biotech company creating biologic medicines

Compensation Overview

$154.2k - $208.6k/yr

+ Annual bonus + Stock-based long-term incentives

Thousand Oaks, CA, USA

In Person

Category
Biology & Biotech (1)
Required Skills
Data Visualization
GMP
Data Analysis

Get referred to Amgen

See people who can refer or advise you

Requirements
  • A doctorate degree and 2 years of manufacturing and operations experience, or a master's degree and 6 years of manufacturing and operations experience, or a bachelor's degree and 8 years of manufacturing and operations experience, or an associate's degree and 10 years of manufacturing and operations experience, or a high school diploma or GED and 12 years of manufacturing and operations experience.
  • At least 2 years of experience directly managing people and/or leading teams, projects, programs, or directing the allocation of resources. Managerial experience may run concurrently with the required technical experience.
Responsibilities
  • Lead, coach, mentor, and develop the manufacturing process owners within the manufacturing organization.
  • Foster a culture of collaboration, continuous improvement, accountability, and high performance across the team.
  • Provide guidance, performance feedback, and support for career development plans for direct reports.
  • Set clear priorities, define role clarity, and establish coverage plans so the production process owner team can flex across site needs, emerging issues, and evolving operational demands.
  • Ensure strong collaboration and coordination between Manufacturing and key partners such as Quality, Facilities and Engineering, Automation, Supply Chain, Maintenance, and other site functions.
  • Provide governance and execution support to ensure smooth, compliant, and reliable manufacturing operations.
  • Manage and improve manufacturing processes to increase productivity, reduce waste, and maintain product quality and compliance.
  • Strengthen process discipline, documentation quality, and operational readiness across site processes.
  • Serve as an escalation point for complex execution topics, ensuring issues are evaluated, decisions are made with the right stakeholders, and actions are closed with discipline.
  • Ensure manufacturing activities are performed in compliance with current good manufacturing practice and all applicable regulatory requirements and internal quality standards.
  • Support inspection and audit readiness by ensuring appropriate documentation, escalation pathways, and governance transparency.
  • Support site teams that own compliance-critical programs, including aseptic compliance and validation-related execution, by helping prioritize resources and drive timely resolution of issues.
  • Ensure disciplined execution and timely closure of quality actions, corrective and preventive actions, and effectiveness verification activities in partnership with Quality and subject matter experts.
  • Support and reinforce a strong safety culture and a safe working environment for all employees.
  • Provide oversight and drive process improvement initiatives aimed at increasing efficiency, improving reliability, reducing costs, and enhancing the drug product manufacturing process.
  • Use lean manufacturing and other continuous improvement tools to identify opportunities and optimize operations.
  • Analyze operational and quality data to identify trends, solve complex problems, and implement corrective actions.
  • Partner with site stakeholders to ensure readiness for new processes, new products, and major operational changes.
  • Support risk identification, issue resolution, and execution readiness across impacted functions and unit operations.
  • Facilitate, or ensure strong facilitation of, key site governance forums used to align priorities, remove barriers, and drive execution.
  • Support the site project governance operating model, including plant project prioritization, by driving disciplined intake, prioritization, execution tracking, and escalation when needed.
  • Act as a point of contact for process owners during troubleshooting and resolution of manufacturing-related issues.
  • Stay current on technological advancements and assess opportunities for adoption in the plant.
  • Support introduction and scale-up of new technologies, equipment, and systems that enhance production capabilities and improve operational performance.
  • Partner cross-functionally to ensure technology-related changes are effectively planned, implemented, and sustained.
Desired Qualifications
  • A bachelor's degree in life sciences, physical sciences, engineering, or a related technical discipline.
  • At least 8 years of manufacturing, operations, technical operations, or process support experience in biotechnology, biopharmaceutical, pharmaceutical, or other highly regulated manufacturing environments.
  • At least 6 years of leadership experience, including direct people leadership and/or leadership of cross-functional teams, programs, or site-level initiatives.
  • At least 2 years of experience managing, coaching, or developing direct reports, technical teams, process owners, or matrixed contributors.
  • Experience in drug product manufacturing operations, including aseptic processing, filling, inspection, packaging, validation execution, or manufacturing readiness.
  • Strong working knowledge of current good manufacturing practice operations and quality systems, including deviations, corrective and preventive actions, change control, effectiveness verification, audit and inspection readiness, standard operating procedures, batch records, and controlled documentation.
  • Demonstrated ability to lead governance forums, drive cross-functional alignment, prioritize competing site needs, and ensure disciplined follow-through on actions and commitments.
  • Experience troubleshooting complex manufacturing, technical, quality, or operational issues in partnership with Quality, Engineering, Automation, Supply Chain, Maintenance, Facilities, and Technical Operations.
  • Demonstrated ability to analyze operational and quality data, identify trends, drive root cause analysis, and implement sustainable corrective and preventive actions.
  • Experience applying lean manufacturing, operational excellence, value stream mapping, capacity planning, waste reduction, or continuous improvement tools to improve manufacturing performance.
  • Strong technical writing and communication skills, with the ability to translate complex technical and operational topics into clear decisions, actions, and governance updates.
  • Experience supporting implementation or sustainment of manufacturing technologies, automation systems, digital tools, manufacturing execution systems, electronic batch records, data visualization platforms, or process monitoring systems.
  • Demonstrated ability to make sound decisions in complex, ambiguous, and highly regulated environments while balancing safety, quality, supply, compliance, and business priorities.
  • Proven ability to build trust, manage conflict effectively, influence without authority, and positively advance the culture of an organization.
  • Strong business acumen, including experience with goal setting, resource planning, budget awareness, inventory control, performance metrics, and manufacturing operating systems.

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • A broad pipeline targets heart disease, obesity, rare disease, inflammation, and cancer.
  • Global reach across roughly 100 countries supports scale and diversification.
  • Legacy cash flows from mature biologics fund new medicine development.

What critics are saying

  • Enbrel faces pricing pressure after Colorado's 70% price-cap challenge.
  • Recent Corlanor and Sensipar recalls expose manufacturing and quality-control weaknesses.
  • Biosimilar competition threatens mature biologics and compresses future margins.

What makes Amgen unique

  • Amgen combines biologics discovery, manufacturing, and commercialization under one integrated platform.
  • Its portfolio spans oncology, cardiovascular, inflammation, bone health, and rare disease.
  • Human genetics and biology guide its drug discovery strategy.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Apr 10th, 2026
Amgen's lung cancer drug tarlatamab wins China approval, seen as $2B+ opportunity

Amgen's lung cancer drug tarlatamab has received approval from China's National Medical Products Administration, according to its development partner BeOne Medicines. The drug is a targeted immunotherapy for adults with extensive-stage small cell lung cancer that has progressed despite chemotherapy. Sold as Imdelltra in the US, tarlatamab is a bispecific antibody designed to connect cancer cells with immune cells, enabling the body's immune system to destroy the cancer. Neither Amgen nor Hong Kong-listed BeOne provided details on launch date or pricing for the Chinese market. Wall Street analysts estimate tarlatamab could generate annual sales exceeding $2 billion for Amgen.

Yahoo Finance
Apr 3rd, 2026
Amgen faces Tavneos liver injury warning as Zai Lab oncology collaboration expands IMDELLTRA pipeline

Amgen faces fresh safety concerns after the FDA warned of severe liver injuries, including vanishing bile duct syndrome, linked to Tavneos (avacopan) in late March 2026. The development adds regulatory risk to the company's investment profile. Separately, Zai Lab announced a global collaboration with Amgen to test its DLL3-targeting ADC alongside Amgen's IMDELLTRA in extensive-stage small cell lung cancer, underscoring the company's ongoing oncology expansion through external partnerships. Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028, requiring 2.3% yearly revenue growth. However, pessimistic analysts model revenues slipping to $34.4 billion with earnings near $5.2 billion, reflecting concerns around pricing pressure, biosimilar competition and rising research and development spend alongside the new safety issues.

Yahoo Finance
Mar 30th, 2026
Amgen stock up 24% since Jim Cramer's June recommendation, beats earnings estimates

Amgen, one of the world's largest pharmaceutical companies, has seen its shares rise 24% since Jim Cramer discussed the stock on Mad Money in June 2025. The company is currently developing the weight loss drug MariTide. Amgen's shares jumped 7.5% in November 2025 after posting third-quarter results that beat analyst expectations, with $9.6 billion in revenue and $5.64 earnings per share against forecasts of $8.98 billion and $5.04 respectively. In February 2026, shares rose 8% following fourth-quarter earnings that also exceeded estimates. Cramer expressed cautious optimism about the biotech company, noting its mid-single-digit earnings growth and potential upside from its GLP-1 drug development. Whilst calling Eli Lilly his preferred GLP-1 play, Cramer said investors "could do a lot worse than Amgen" for a bargain option.

Yahoo Finance
Mar 25th, 2026
Wells Fargo lifts Amgen price target to $390, cites $20B myasthenia gravis market potential by 2036

Wells Fargo has raised its price target on Amgen to $390 from $375, maintaining an Equal Weight rating. The firm cited emerging therapies including CD20, BAFF/APRIL and next-generation complement inhibitors as potential drivers that could expand the generalized myasthenia gravis market threefold over the next decade, potentially reaching $15 billion in US sales and $20 billion globally by 2036. Separately, Jefferies initiated coverage on Amgen with a Hold rating and $350 price target on 10 March, noting the stock has gained approximately 35% over the past six months. Last month, Amgen reported fourth-quarter adjusted earnings per share of $5.29, beating the $4.76 consensus estimate, on revenue of $9.9 billion versus $9.45 billion expected.

Yahoo Finance
Mar 15th, 2026
Amgen joins TrumpRx discount scheme and lifts dividend to $2.52 per share

Amgen has announced a $2.52 per-share second-quarter dividend and joined the government-run TrumpRx platform to offer discounted drugs including Amjevita, Aimovig and Repatha. The company is also preparing for its 11 March presentation at the Leerink Global Healthcare Conference in Miami. The moves come alongside double-digit revenue and earnings per share growth in 2025 and advances in obesity and oncology programmes. However, the TrumpRx discounting could pressure net pricing as Amgen invests heavily in late-stage trials and manufacturing expansion. Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028, requiring 2.3% yearly revenue growth. Some analysts see a tougher outlook, with revenue potentially drifting towards $34.4 billion and earnings around $5.2 billion.